

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,402,660 B2
APPLICATION NO. : 09/918715
DATED : July 22, 2008
INVENTOR(S) : Brad St. Croix et al.

Page 1 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Prior to the Specification in Column 1, Line 1
Please insert the appended Tables 1-4.

Table 1. Previously characterized and novel Pan Endothelial Markers (PEMs).

The most abundant tags derived by summing the tags from Normal EC (N-EC's) and Tumor EC (T-EC's) SAGE libraries are listed in descending order. N-EC and T-EC SAGE libraries contained 96,694 and 96,588 SAGE tags respectively. For comparison, the corresponding number of SAGE tags found in cultured human umbilical vein endothelial cells (HUVEC), human dermal microvascular endothelial cells (HMVEC), and non-endothelial cell lines (Cell Lines) are shown. The HUVEC SAGE library contained 290,000 tags and the HMVEC library 111,000 tags. Non-endothelial cell lines consisted of 1.8x10⁶ tags derived from a total of 14 different cancer cell lines including colon, breast, lung, and pancreatic cancers, as well as one non-transformed keratinocyte cell line, two kidney epithelial cell lines, and normal monocytes. Tag numbers for each group were normalized to 100,000 transcripts. A 'Description' of the gene product corresponding to each tag is given, followed by alternative names in parenthesis. The sequence CATG precedes all tags and the 15th base (11th shown) was determined as previously described by Velculescu et al. (Nat Genet 1999 Dec;23(4):387-8).

| no. | Tag Sequence | N-EC's | T-EC's | HUVEC | HMVEC | Cell Lines | Description |
|-----|--------------|--------|--------|-------|-------|------------|---|
| 1 | CATATCATTAA | 247 | 501 | 130 | 87 | 2 | angiomodulin (ANG, IGFBP-7, IGFBP-rP1, Mac25, TAF) |
| 2 | TGCACTTCAAG | 328 | 141 | 0 | 0 | 0 | hevin |
| 3 | TTTGACCTTT | 165 | 84 | 191 | 115 | 4 | connective tissue growth factor (CTGF, IGFBP-rP2) |
| 4 | CCCTTGTCGG | 131 | 104 | 1 | 1 | 0 | ESTs |
| 5 | TTGCTGACTTT | 73 | 131 | 2 | 14 | 1 | collagen, type VI, alpha 1 |
| 6 | ACCATTGGATT | 102 | 67 | 0 | 0 | 2 | interferon induced transmembrane protein 1 (9-27, Leu 13) |
| 7 | ACACTTCTTTC | 104 | 44 | 60 | 62 | 2 | guanine nucleotide binding protein 11 |
| 8 | TTCTGCTCTTG | 71 | 67 | 118 | 72 | 0 | von Willebrand factor |
| 9 | TCCCTGGCAGA | 66 | 68 | 3 | 13 | 3 | cysteine-rich protein 2 (CRP-2, ESP-1, SMLIM) |
| 10 | TAATCCTCAAG | 26 | 106 | 34 | 16 | 1 | collagen, type XVIII, alpha 1 |
| 11 | ATGTCTTTTCT | 58 | 65 | 17 | 17 | 3 | insulin-like growth factor-binding protein 4 |
| 12 | GGGATTAAAGC | 40 | 67 | 30 | 14 | 2 | CD146 (S-Endo 1, P1H12, Muc18, MCAM, Mel-CAM) |
| 13 | TTAGTGTCGTA | 38 | 69 | 9 | 13 | 0 | SPARC (osteonectin, BM-40) |
| 14 | TTCTCCCAAT | 20 | 86 | 16 | 64 | 2 | collagen, type IV, alpha 2 |
| 15 | GTGCTAAGCGG | 24 | 74 | 0 | 10 | 2 | collagen, type VI, alpha 2 |
| 16 | GTTTATGGATA | 35 | 56 | 11 | 11 | 1 | matrix Gla protein (MGP) |
| 17 | CCCTTTCACAC | 52 | 33 | 0 | 0 | 0 | ESTs, Weakly similar to HPBRII-7 protein |
| 18 | TGTTCTGGAGA | 58 | 27 | 18 | 56 | 2 | gap junction protein, alpha 1, 43kD (connexin 43) |

| | | | | | | | |
|----|--------------|----|----|----|----|---|--|
| 19 | AAGATCAAGAT | 34 | 50 | 2 | 4 | 1 | actin, alpha 1, skeletal muscle / actin, alpha 2, smooth muscle, aorta |
| 20 | TCTCTGAGCAT | 32 | 48 | 0 | 0 | 0 | aggrecanase 1 (metalloproteinase with thrombospondin type 1 motifs, 4) |
| 21 | CAGGTTTCATA | 22 | 56 | 0 | 0 | 0 | small Inducible cytokine subfamily B (Cys-X-Cys), member 14 (BRAK) |
| 22 | GCACAAGTTCT | 43 | 25 | 6 | 22 | 0 | calcitonin receptor-like receptor activity modifying protein 2 |
| 23 | AGCTTGTTGCC | 45 | 23 | 0 | 0 | 0 | calcitonin receptor-like receptor activity modifying protein 3 |
| 24 | CTTCTGGATAA | 13 | 54 | 12 | 0 | 0 | cell division cycle 42 (GTP-binding protein, 25kD) |
| 25 | CAACAATAATA | 42 | 25 | 13 | 6 | 0 | ESTs |
| 26 | ACCGGGCGCCCG | 50 | 15 | 0 | 0 | 0 | tetranectin (plasminogen-binding protein) |
| 27 | GGAAGCTAAGT | 35 | 27 | 0 | 5 | 1 | osteoblast specific factor 2 (fasciclin I-like) |
| 28 | GCAATTTAACC | 38 | 21 | 0 | 3 | 0 | solute carrier family 21 (prostaglandin transporter), member 2 |
| 29 | GATAACTACAT | 18 | 35 | 4 | 4 | 0 | angiomodulin (ANG, IGFBP-7, IGFBP-rP1, Mac25, TAF) |
| 30 | TATGAGGGTAA | 19 | 30 | 40 | 2 | 0 | regulator of G-protein signalling 5 |
| 31 | CCACGGGATTC | 10 | 39 | 0 | 0 | 0 | collagen, type III, alpha 1 |
| 32 | TTTACAAAGAG | 26 | 21 | 0 | 1 | 1 | carboxypeptidase E |
| 33 | CCCAGTAAGAT | 22 | 25 | 0 | 16 | 1 | cysteine and glycine-rich protein 2 (LIM domain only, smooth muscle) |
| 34 | ACAAAGCATTT | 26 | 20 | 0 | 14 | 1 | Human Insulin-like growth factor binding protein 5 (IGFBP5) mRNA |
| 35 | GCCTGTCCCTC | 8 | 38 | 22 | 11 | 0 | ESTs / biglycan |
| 36 | TACTTTATAAG | 25 | 21 | 1 | 1 | 0 | metalloproteinase with thrombospondin type 1 motifs (ADAMTS1, METH-1) |
| 37 | TGTTTAATACA | 15 | 29 | 2 | 1 | 1 | ESTs / erythrocyte membrane protein band 4.1-like 2 |
| 38 | GTCCCTGCCTT | 18 | 25 | 1 | 1 | 0 | glutathione S-transferase M2 (muscle) |
| 39 | GAGCCATCATA | 21 | 21 | 2 | 2 | 1 | ESTs / GTP-binding protein |

| | | | | | | | |
|----|--------------|----|----|----|----|---|---|
| | | | | | | | overexpressed in skeletal muscle |
| 40 | GGCCCTACAGT | 26 | 13 | 2 | 3 | 0 | ESTs / KIAA0821 protein |
| 41 | GCTAACCCCTG | 7 | 31 | 0 | 1 | 0 | ESTs |
| 42 | ATCACACAGCT | 19 | 18 | 0 | 0 | 0 | thyroid and eye muscle autoantigen D1 (64kD) |
| 43 | ACAAGTACTGT | 18 | 19 | 36 | 27 | 0 | cadherin 5, VE-cadherin (vascular epithelium) |
| 44 | TCACCGTGGAC | 20 | 17 | 0 | 1 | 0 | selectin P (granule membrane protein 140kD, antigen CD62) |
| 45 | ACATTCCAAGT | 18 | 18 | 0 | 1 | 1 | tissue inhibitor of metalloproteinase 3 |
| 46 | GAGCCTGGATA | 6 | 29 | 0 | 0 | 0 | chondroitin sulfate proteoglycan 4 (melanoma-associated) |
| 47 | GGCACTCCTGT | 22 | 13 | 19 | 12 | 0 | ESTs |
| 48 | TCACAGCCCCC | 20 | 15 | 8 | 5 | 0 | ESTs |
| 49 | TGCCAGGTGCA | 10 | 23 | 0 | 1 | 0 | albumin |
| 50 | TGGGAAACCTG | 11 | 22 | 0 | 1 | 1 | eukaryotic translation initiation factor 4 gamma, 1 |
| 51 | TTTCATCCACT | 20 | 13 | 0 | 2 | 0 | ESTs, KIAA0362 protein |
| 52 | AACAGGGGCCA | 15 | 18 | 0 | 0 | 1 | ESTs / Interferon, alpha-inducible protein (clone IFI-6-16) |
| 53 | ACTGAAAGAAG | 6 | 26 | 0 | 0 | 1 | complement component 1, s subcomponent |
| 54 | ACCGTTCCTGTA | 8 | 24 | 10 | 6 | 0 | transcription factor 4 |
| 55 | ATACTATAATT | 25 | 6 | 2 | 0 | 0 | ESTs |
| 56 | TTTGTATAGAA | 17 | 15 | 4 | 5 | 1 | KIAA0393 protein |
| 57 | GTAATGACAGA | 20 | 11 | 1 | 1 | 1 | stannocalcin |
| 58 | AATAGGGGAAA | 13 | 19 | 4 | 1 | 0 | ESTs, KIAA1075 protein |
| 59 | GTGCTACTTCT | 5 | 25 | 2 | 18 | 0 | collagen, type IV, alpha 1 |
| 60 | CCGGCCCCCTCC | 6 | 24 | 0 | 0 | 1 | peanut (Drosophila)-like 2 |
| 61 | TTGAATTGT | 19 | 10 | 1 | 1 | 0 | RNA-binding protein gene with multiple splicing |
| 62 | CGAGAGTGTGA | 22 | 6 | 0 | 0 | 0 | ESTs |
| 63 | CCCTGTTACAGC | 14 | 15 | 38 | 24 | 0 | tyrosine kinase with IgG and EGF homology domains (Tie) |
| 64 | CAGATGGAGGC | 18 | 10 | 1 | 9 | 0 | ESTs |
| 65 | AGGCTCCTGGC | 8 | 20 | 0 | 0 | 0 | ESTs |
| 66 | TCTGCTTCTAG | 20 | 8 | 40 | 15 | 0 | ESTs |

| | | | | | | | |
|----|-------------|----|----|----|----|---|---|
| 67 | GGCTTAGGATG | 18 | 9 | 10 | 14 | 0 | ESTs |
| 68 | GGTGTGCGG | 6 | 21 | 0 | 0 | 1 | ESTs |
| 69 | ACAAGTACCCA | 5 | 22 | 4 | 5 | 0 | P311 protein |
| 70 | CTTCTCTGAG | 18 | 9 | 1 | 4 | 1 | basic transcription element binding protein 1 |
| 71 | GCTAATAATGT | 10 | 17 | 0 | 2 | 0 | KIAA1077 protein |
| 72 | TGTGCTTTTTT | 10 | 15 | 1 | 4 | 0 | KIAA0758 protein / protein kinase, cAMP-dependent, catalytic, alpha |
| 73 | CATCACGGATC | 17 | 8 | 0 | 1 | 0 | interleukin 1 receptor, type I |
| 74 | GCAGCAGCAGC | 6 | 18 | 0 | 2 | 0 | T-box 2 |
| 75 | TGACTGTATTA | 13 | 11 | 0 | 0 | 0 | ESTs / amine oxidase, copper containing 3 (vascular adhesion protein 1) |
| 76 | GAATGCTCTTG | 6 | 18 | 0 | 11 | 0 | gap junction protein, alpha 4, 37kD (connexin 37) |
| 77 | GTAGTCTGGA | 18 | 6 | 0 | 5 | 0 | ESTs, clone 23698 mRNA |
| 78 | TCCCTCTCTC | 6 | 17 | 0 | 0 | 0 | periodontal ligament fibroblast protein |
| 79 | GGGCAGTGGCT | 5 | 18 | 12 | 5 | 0 | ESTs, DKFZP586B0621 protein |
| 80 | AAATATGTGTT | 19 | 4 | 13 | 3 | 0 | ESTs |
| 81 | GTCATTTTCTA | 11 | 11 | 10 | 2 | 0 | ESTs / transcription factor 8 (represses Interleukin 2 expression) |
| 82 | CTCTCCAAACC | 14 | 8 | 0 | 0 | 0 | complement component 1 inhibitor (angioedema, hereditary) |
| 83 | TTAATGTGTAA | 4 | 18 | 0 | 0 | 0 | guanylate cyclase 1, soluble, beta 3 |
| 84 | TCAAGCAATCA | 13 | 9 | 0 | 1 | 0 | ESTs |
| 85 | GAAGACACTTG | 15 | 7 | 1 | 0 | 0 | ESTs |
| 86 | GGGTAGGGTGA | 6 | 15 | 0 | 0 | 1 | Integrin, alpha 7 |
| 87 | TGGAACAGTGA | 10 | 10 | 10 | 5 | 0 | ESTs |
| 88 | GAGTGGCTACC | 10 | 9 | 0 | 0 | 0 | ESTs |
| 89 | GTCAGGGTCCC | 13 | 7 | 0 | 9 | 0 | decidual protein induced by progesterone |
| 90 | GTCAGTCACTT | 14 | 6 | 4 | 1 | 0 | hairy (Drosophila)-homolog |
| 91 | AGCAGAGACAA | 14 | 6 | 1 | 10 | 0 | natriuretic peptide receptor A - guanylate cyclase A |
| 92 | AGCGATGGAGA | 9 | 10 | 0 | 0 | 0 | ESTs |
| 93 | CGTGGGGTGTA | 9 | 10 | 17 | 3 | 0 | |

Table 2. Previously characterized and novel Tumor Endothelial Markers (TEMs).

The top 46 tags with the highest tumor EC (T-EC's) to normal EC (N-EC's) tag ratios are listed in descending order. To calculate tag ratios, a value of 0.5 was assigned in cases where zero tags were observed. The SAGE libraries are the same as those listed in Table 1. Tag numbers for each group were normalized to 100,000 transcripts. A 'Description' of the gene product corresponding to each tag is given, followed by alternative names in parenthesis. [†]: multiple tags for this gene are due to alternative polyadenylation sites.

| no. | Tag Sequence | N-EC's | T-EC's | HUVEC | HMVEC | Cell Lines | Description |
|-----|--------------|--------|--------|-------|-------|------------|--|
| 1 | GGGGCTGCCCA | 0 | 28 | 0 | 2 | 0 | TEM1 |
| 2 | GATCTCCGTGT | 0 | 25 | 0 | 0 | 0 | TEM2 |
| 3 | CATTTTATCT | 0 | 23 | 0 | 0 | 0 | TEM3 |
| 4 | CTTCTTTGAG | 0 | 22 | 6 | 20 | 1 | regulated in glioma-like 7-1 (Dkk-3/ REIC) |
| 5 | TATTAACCTC | 0 | 21 | 1 | 3 | 1 | TEM4 |
| 6 | CAGGAGACCCC | 0 | 16 | 2 | 0 | 0 | MMP-11 (stromelysin 3) |
| 7 | GGAAATGTCAA | 1 | 31 | 53 | 22 | 1 | MMP-2 (gelatinase A, 72kD type IV collagenase) |
| 8 | CCTGGTTCAGT | 0 | 15 | 0 | 0 | 0 | ESTs |
| 9 | TTTTTAAGAAC | 0 | 14 | 1 | 4 | 0 | TEM5 |
| 10 | TTTGGTTTTCC | 5 | 139 | 0 | 16 | 0 | collagen, type I, alpha 2, transcript A [†] |
| 11 | ATTTTGTATGA | 0 | 13 | 4 | 8 | 0 | nidogen (entactin) |
| 12 | ACTTTAGATGG | 1 | 23 | 0 | 15 | 0 | collagen, type VI, alpha 3 |
| 13 | GAGTGAGACCC | 3 | 63 | 0 | 0 | 1 | Thy-1 cell surface antigen |
| 14 | GTACACACACC | 0 | 10 | 0 | 0 | 0 | ESTs / cystatin S |
| 15 | CCACAGGGGAT | 2 | 38 | 0 | 2 | 1 | collagen, type III, alpha 1 |
| 16 | TTAAAAGTCAC | 1 | 19 | 1 | 3 | 1 | TEM6 |
| 17 | ACAGACTGTTA | 4 | 74 | 0 | 0 | 0 | TEM7 |
| 18 | CCACTGCAACC | 1 | 18 | 0 | 1 | 0 | |
| 19 | CTATAGGAGAC | 1 | 18 | 1 | 1 | 0 | TEM8 |
| 20 | GTTCCACAGAA | 0 | 9 | 0 | 3 | 0 | collagen, type I, alpha 2, transcript B [†] |
| 21 | TACCACCTCCC | 0 | 9 | 4 | 1 | 1 | ESTs / pregnancy specific beta-1-glycoprotein 1 |
| 22 | GCCCTTTCTCT | 1 | 17 | 3 | 1 | 2 | TEM9 (endo180 lectin) |
| 23 | TTAAATAGCAC | 2 | 33 | 0 | 4 | 0 | collagen, type I, alpha 1 |
| 24 | AGACATACTGA | 1 | 16 | 1 | 0 | 0 | ESTs, DKFZP434G162 protein |
| 25 | TCCCCCAGGAG | 1 | 16 | 0 | 0 | 0 | bone morphogenetic protein 1 (metalloprotease) |

| | | | | | | | |
|----|-------------|----|-----|---|----|---|---|
| 26 | AGCCCAAAGTG | 0 | 8 | 0 | 0 | 0 | |
| 27 | ACTACCATAAC | 0 | 8 | 0 | 0 | 0 | slit (Drosophila) homolog 3 (MEGF5) |
| 28 | TACAAATCGTT | 0 | 8 | 0 | 0 | 0 | KIAA0672 gene product |
| 29 | TTGGGTGAAAA | 0 | 8 | 0 | 0 | 0 | ESTs |
| 30 | CATTATCCAAA | 0 | 8 | 0 | 0 | 0 | integrin, alpha 1 |
| 31 | AGAAACCACGG | 0 | 8 | 2 | 7 | 0 | collagen, type IV, alpha 1 |
| 32 | ACCAAAACCAC | 0 | 8 | 0 | 3 | 0 | |
| 33 | TGAAATAAAC | 0 | 8 | 3 | 1 | 1 | |
| 34 | TTTGGTTTCC | 1 | 15 | 0 | 0 | 0 | ESTs |
| 35 | GTGGAGACGGA | 1 | 15 | 1 | 2 | 1 | ESTs |
| 36 | TTTGTTGTGTA | 1 | 14 | 2 | 0 | 0 | collagen, type XII, alpha 1 |
| 37 | TTATGTTTAAT | 3 | 39 | 0 | 0 | 1 | lumican |
| 38 | TGGAAATGACC | 15 | 179 | 0 | 40 | 0 | ESTs / collagen, type I, alpha 1 |
| 39 | TGCCACACAGT | 1 | 13 | 0 | 2 | 0 | transforming growth factor, beta 3 |
| 40 | GATGAGGAGAC | 3 | 35 | 0 | 18 | 1 | collagen, type I, alpha 2, transcript C1 |
| 41 | ATCAAAGGTTT | 2 | 23 | 0 | 0 | 0 | ESTs, DKFZp5640222 mRNA |
| 42 | AGTCACATAGT | 1 | 11 | 2 | 0 | 0 | ESTs / cell division cycle 42 (GTP-binding protein) |
| 43 | TTCGGTTGGTC | 4 | 45 | 0 | 19 | 0 | |
| 44 | CCCCACACGGG | 2 | 21 | 0 | 0 | 0 | ESTs |
| 45 | GGCTTGCCCTT | 1 | 10 | 0 | 10 | 1 | |
| 46 | ATCCCTTCCCG | 1 | 10 | 1 | 0 | 0 | peanut-like protein 1 |

Table 3. Previously characterized and novel Normal Endothelial Markers (NEMs).

The top 33 tags with the highest normal EC (N-EC's) to tumor EC (T-EC's) tag ratios are listed in descending order. To calculate tag ratios, a value of 0.5 was assigned in cases where zero tags were observed. The SAGE libraries are the same as those listed in Table 1. Tag numbers for each group were normalized to 100,000 transcripts. A 'Description' of the gene product corresponding to each tag is given, followed by alternative names in parenthesis.

| no. | Tag Sequence | N-EC's | T-EC's | HUVEC | HMVEC | Cell Lines | Description |
|-----|--------------|--------|--------|-------|-------|------------|---|
| 1 | TCTCACGTCTC | 26 | 0 | 0 | 0 | 0 | mucosal vascular addressin cell adhesion molecule 1 |
| 2 | CTAGCGTTTTA | 19 | 0 | 4 | 14 | 0 | serum deprivation response (phosphatidylserine-binding protein) |
| 3 | GTGGCTGACGC | 18 | 0 | 1 | 0 | 0 | ESTs / Inter cellular adhesion molecule 4 |
| 4 | CTCTTAAAAA | 34 | 1 | 1 | 0 | 0 | small inducible cytokine subfamily A (Cys-Cys), member 14 |
| 5 | TGGGAAGAGGG | 16 | 0 | 3 | 4 | 1 | ESTs |
| 6 | GTTTAAGGATG | 16 | 0 | 0 | 0 | 0 | ESTs |
| 7 | CTTTGTTTTGC | 15 | 0 | 56 | 32 | 1 | endothelin 1 |
| 8 | ATTGCCAATCT | 14 | 0 | 0 | 4 | 0 | TU3A protein |
| 9 | TGTTGAAAAA | 21 | 1 | 1 | 0 | 0 | E-selectin (endothelial adhesion molecule 1) |
| 10 | ACAAAAAGGCC | 21 | 1 | 0 | 6 | 0 | TU3A protein |
| 11 | AAGATGCACAC | 21 | 1 | 1 | 1 | 1 | phosphodiesterase I - nucleotide pyrophosphatase 2 (autotaxin) |
| 12 | GTAGAGGAAAA | 10 | 0 | 0 | 9 | 0 | |
| 13 | TTGTTCAAGGG | 10 | 0 | 0 | 1 | 0 | ESTs |
| 14 | CTCTTCAAAAA | 19 | 1 | 1 | 0 | 0 | small inducible cytokine subfamily A, member 14 |
| 15 | TATTAATAG | 18 | 1 | 6 | 9 | 1 | transforming growth factor, beta receptor II (70-80kD) |
| 16 | GAATTCACCAG | 9 | 0 | 1 | 14 | 0 | ESTs |
| 17 | AAGGAGAACTG | 9 | 0 | 0 | 0 | 0 | small inducible cytokine subfamily A, member 14 |
| 18 | AATATCTGACT | 9 | 0 | 2 | 2 | 2 | active BCR-related gene |
| 19 | TCAGTGACCAG | 17 | 1 | 4 | 7 | 2 | protein kinase C eta |
| 20 | GCAAAGTGCCC | 32 | 2 | 1 | 5 | 0 | ESTs |
| 21 | TAAATACTTGT | 8 | 0 | 2 | 0 | 0 | ESTs |

| | | | | | | | |
|----|-------------|----|---|----|----|---|---|
| 22 | GTCACAAATTT | 8 | 0 | 1 | 0 | 0 | ESTs |
| 23 | ATAACCTGCAG | 8 | 0 | 0 | 0 | 0 | signaling lymphocytic activation molecule |
| 24 | TGCATCTGTGC | 46 | 3 | 1 | 1 | 0 | ESTs / glycogenin 2 |
| 25 | TAAAGGCACAG | 15 | 1 | 4 | 3 | 0 | LIM binding domain 2 |
| 26 | GACCGCGGCTT | 73 | 5 | 11 | 7 | 0 | claudin 5 |
| 27 | ACTCCGGTGTG | 14 | 1 | 0 | 8 | 0 | ESTs |
| 28 | CTTCTACCTA | 27 | 2 | 3 | 1 | 0 | GTP-binding protein |
| 29 | TCGTGCTTTGT | 13 | 1 | 0 | 0 | 0 | ESTs |
| 30 | GAGCAGTGCTG | 13 | 1 | 4 | 2 | 1 | feline sarcoma viral (v-fes) - Fujinami avian sarcoma viral (v-fps) homolog |
| 31 | CTCTAAAAAA | 10 | 1 | 0 | 1 | 0 | ESTs |
| 32 | GAAACCCGGTA | 10 | 1 | 0 | 0 | 1 | phospholipase C, beta 4 |
| 33 | AACACAGTGCC | 10 | 1 | 7 | 15 | 1 | ESTs |

Table 4. Detection of transcripts in various tumor types by RT-PCR and in situ hybridization (ISH).

The “+” sign indicates the presence of a robust RT-PCR product or strong positive staining of vessels by in situ hybridization. The “-” sign indicates an undetectable signal by in situ hybridization or an absent or barely detectable transcript by RT-PCR. The “+/-” sign indicates a very weak signal in a limited number of vessels by in situ hybridization. “ND” indicates not determined.

| | | TEM1 | TEM3 | TEM4 | TEM5 | TEM7 | TEM8 | TEM9 | vWF | Hevin |
|---------------|-------------|------|------|------|------|------|------|------|-----|-------|
| RT-PCR | ColonNor. | - | - | - | - | - | - | - | + | ND |
| | Colon Tum. | + | + | + | + | + | + | + | + | ND |
| ISH | ColonNor. | - | - | - | - | - | - | - | + | + |
| | Colon Tum. | + | + | + | + | + | + | + | + | + |
| | Liver Met. | + | +/- | + | + | + | + | + | +/- | ND |
| | Lung Tum. | + | ND | + | + | + | + | + | + | + |
| | Brain Tum. | + | ND | ND | ND | + | ND | ND | + | + |
| | Corpus Lut. | + | + | + | + | + | - | + | + | + |
| | Wound | + | ND | + | ND | +/- | +/- | ND | + | + |

* hevin was localized to both endothelial cells and malignant cells in brain tissue.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,402,660 B2
APPLICATION NO. : 09/918715
DATED : July 22, 2008
INVENTOR(S) : Brad St. Croix et al.

Page 11 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Column 40, Line 48

Please insert the following claims:

--33. The isolated molecule of claim 1 wherein said molecule binds to TEM17 at least 7 times more than to irrelevant antigen or antigen mixture.

34. The isolated molecule of claim 1 wherein said molecule binds to TEM17 at least 10 times more than to irrelevant antigen or antigen mixture.--

Signed and Sealed this

Twenty-eighth Day of October, 2008

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looping initial "J" and a distinct "D".

JON W. DUDAS
Director of the United States Patent and Trademark Office